We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+9.35%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$846M
AUM Growth
+$95.3M
Cap. Flow
+$37.1M
Cap. Flow %
4.39%
Top 10 Hldgs %
28.99%
Holding
143
New
11
Increased
56
Reduced
23
Closed
11

Top Buys

Rank Stock Value
1
EW icon
Edwards Lifesciences
EW
+$7.11M
2
IART icon
Integra LifeSciences
IART
+$6.94M
3
CI icon
Cigna
CI
+$6.83M
4
ALKS icon
Alkermes
ALKS
+$5.7M
5
IQV icon
IQVIA
IQV
+$5.62M

Top Sells

Rank Stock Value
1
AKRX
Akorn Inc
AKRX
+$11.9M
2
CNC icon
Centene
CNC
+$9.33M
3
INCY icon
Incyte
INCY
+$8.09M
4
LGND icon
Ligand Pharmaceuticals
LGND
+$6.18M
5
ALR
Alere Inc
ALR
+$5.78M

Sector Composition

Rank Sector Weight
1 Healthcare 92.73%
2 Financials 0.93%
3 Industrials 0.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ICPT
101
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$1.03M 0.12%
8,500
– –
BIB icon
102
ProShares Ultra NASDAQ Biotechnology
BIB
$84.1M
$1.01M 0.12%
+19,000
New +$927K
UTHR icon
103
United Therapeutics
UTHR
$22.7B
$1.01M 0.12%
7,800
– –
IRTC icon
104
iRhythm Holdings
IRTC
$3.64B
$999K 0.12%
+23,500
New +$856K
PEN icon
105
Penumbra
PEN
$12.5B
$992K 0.12%
11,300
+6,300
+126% +$535K
PFE icon
106
Pfizer
PFE
$143B
$981K 0.12%
30,777
-21,923
-42% -$691K
GKOS icon
107
Glaukos
GKOS
$9.21B
$933K 0.11%
22,500
+2,500
+13% +$108K
HMSY
108
DELISTED
HMS Holdings Corp.
HMSY
$925K 0.11%
+50,000
New +$962K
PODD icon
109
Insulet
PODD
$11.4B
$872K 0.1%
17,000
+2,000
+13% +$86.8K
NKTR icon
110
Nektar Therapeutics
NKTR
$2.31B
$841K 0.1%
2,867
-8,600
-75% -$2.49M
EVHC
111
DELISTED
Envision Healthcare Holdings Inc
EVHC
$816K 0.1%
13,026
– –
QTNT
112
DELISTED
Quotient Limited Ordinary Shares
QTNT
$810K 0.1%
2,750
– –
TDOC icon
113
Teladoc Health
TDOC
$1.7B
$781K 0.09%
22,500
+2,500
+13% +$72.8K
COTV
114
DELISTED
Cotiviti Holdings, Inc.
COTV
$780K 0.09%
+21,000
New +$825K
CEMP
115
DELISTED
Cempra, Inc.
CEMP
$759K 0.09%
165,000
– –
MDCO
116
DELISTED
Medicines Co
MDCO
$741K 0.09%
19,500
-2,000
-9% -$89.1K
NVRO
117
DELISTED
NEVRO CORP.
NVRO
$722K 0.09%
9,700
+1,000
+11% +$80.1K
VAR
118
DELISTED
Varian Medical Systems, Inc.
VAR
$722K 0.09%
7,000
– –
SGRY icon
119
Surgery Partners
SGRY
$2.09B
$705K 0.08%
31,000
+20,500
+195% +$422K
HCM icon
120
HUTCHMED
HCM
$1.86B
$682K 0.08%
+29,242
New +$600K
DVA icon
121
DaVita
DVA
$15.2B
$648K 0.08%
10,000
– –
GWPH
122
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$602K 0.07%
6,000
– –
TBPH icon
123
Theravance Biopharma
TBPH
$877M
$575K 0.07%
14,428
– –
TRHC
124
DELISTED
Tabula Rasa HealthCare, Inc. Common Stock
TRHC
$555K 0.07%
+36,907
New +$498K
ITCI
125
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$497K 0.06%
+40,000
New +$464K
2 3 4
5
6

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q2 2017 Portfolio in Review

As of Q2 2017, Bellevue Group held 143 positions worth $846M, up 13% from $750M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Bellevue Group deployed $37.1M of net new capital in Q2 2017, opening 11 new positions and adding to 56 existing holdings. Its largest new stake was IQVIA: 66,520 shares worth $5.95M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 92% a quarter earlier, followed by Financials and Industrials.

On the sell side, the largest reduction was Centene, an estimated $9.33M trimmed.

  • Bellevue Group's largest Q2 2017 buy was IQVIA: 66,520 shares worth $5.95M.
  • Bellevue Group added most to Edwards Lifesciences in Q2 2017, an estimated $7.11M increase.
  • Bellevue Group's biggest Q2 2017 reduction was Centene, cutting an estimated $9.33M.
  • Bellevue Group fully exited Akorn Inc in Q2 2017, selling an estimated $11.9M.
  • Bellevue Group's ten largest holdings make up 29% of its $846M portfolio in Q2 2017.
  • Bellevue Group opened 11 new positions and closed 11 in Q2 2017.
  • Bellevue Group's portfolio value rose 13% quarter-over-quarter to $846M.

Based on Bellevue Group's 13F filing for Q2 2017, filed 14 Aug 2017.